Approval Beckons For Orchard’s Gene Therapy Libmeldy

Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.    

• Source: Shutterstock

Orchard Therapeutics Limited is hoping to gain the first approval by the end of the year for its one-time gene therapy for metachromatic leukodystrophy (MLD), Libmeldy (OTL-2000), in the EU. A launch is expected to follow in early 2021.

Libmeldy (cryopreserved autologous CD34+ cells encoding the arylsulfatase-A, or ARSA, gene) has been granted a positive opinion by the European...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip